Hepatitis delta virus detected in salivary glands of Sjögren’s syndrome patients and recapitulates a Sjögren’s syndrome-like phenotype in vivo

Pathogens and Immunity

Volumn 1, Issue 1, 2016, Pages 12-40

  Weller, Melodie L ^a   Gardener, Matthew R ^a   Bogus, Zoe C ^a   Smith, Michael A ^a   Astorri, Elisa ^b   Michael, Drew G ^a   Michael, Donald A ^a   Zheng, Changyu ^a   Burbelo, Peter D ^a   Lai, Zhennan ^a   Wilson, Paul A ^c   Swaim, William ^a   Handelman, Beverly ^a   Afione, Sandra A ^a   Bombardieri, Michele ^b   Chiorini, John A ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HDV; Hepatitis D Virus; Hepatitis Delta Virus; Sjogrens syndrome; Sjogren s syndrome; Sj grens syndrome; Sj gren s syndrome; Viral mediated autoimmunity; Xerophthalmia; Xerostomia

Indexed keywords

EID: 85010262196     PISSN: None     EISSN: 24692964     Source Type: Journal    
DOI: 10.20411/pai.v1i1.72     Document Type: Article

References (57)

1. Knobler SL, O’Connor S, Lemon SM, Najafi M, eds. The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2004.
2. Igoe A, Scofield RH. Autoimmunity and infection in Sjögren’s syndrome. Current opinion in rheumatology. 2013 Jul;25(4):480-7. Epub 2013/05/31. eng. doi: 10.1097/BOR.0b013e32836200d2
3. Meyer O. Interferons and autoimmune disorders. Joint, bone, spine: Revue du rhumatisme. 2009 Oct;76(5):464-73. Epub 2009/09/24. doi: 10.1016/j.jbspin.2009.03.012
4. Nandula SR, Dey P, Corbin KL, Nunemaker CS, Bagavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. Journal of oral pathology & medicine: Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2013 Jan;42(1):66-72. PubMed PMID: 22672212. Epub 2012/06/08. doi: 10.1111/j.1600-0714.2012.01181.x
5. Nguyen CQ, Peck AB. The Interferon-Signature of Sjogren’s Syndrome: How Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases. Frontiers in immunology. 2013;4:142. Epub 2013/07/13. doi: 10.3389/fimmu.2013.00142
6. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Current opinion in rheumatology. 2013 Mar;25(2):248-53. Epub 2012/12/20. doi: 10.1097/BOR.0b013e32835c7e32
7. Vakaloglou KM, Mavragani CP. Activation of the type I interferon pathway in primary Sjogren’s syndrome: An update. Current opinion in rheumatology. 2011 Sep;23(5):459-64. Epub 2011/07/16. doi: 10.1097/BOR.0b013e328349fd30
8. Yao Y, Liu Z, Jallal B, Shen N, Ronnblom L. Type I interferons in Sjogren’s syndrome. Autoimmunity reviews. 2013 Mar;12(5):558-66. Epub 2012/12/04. doi: 10.1016/j.autrev.2012.10.006
9. Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjogren’s syndrome: Where are we now? Clinical and experimental rheumatology. 2007 Jan-Feb;25(1):1-4. Epub 2007/04/10.
10. Bureau USC. U.S. and World Population Clock 2013 [cited 2013 12/20/2013]. 7131957000 at 3pm on 12/20/13; M. Weller]. Available from: Http://www.census.gov/popclock/.
11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Annals of the rheumatic diseases. 2002 Jun;61(6):554-8. Epub 2002/05/15.
12. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA: The journal of the American Medical Association. 2013 Nov 6;310(17):1854-5. Epub 2013/11/07. doi: 10.1001/jama.2013.278448
13. Al-Hashimi I, Khuder S, Haghighat N, Zipp M. Frequency and predictive value of the clinical manifestations in Sjogren’s syndrome. Journal of oral pathology & medicine: Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2001 Jan;30(1):1-6. Epub 2001/01/05.
14. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Wolff A. Sjogren’s syndrome: The diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia. Journal of oral pathology & medicine: Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2005 Jan;34(1):1-6. Epub 2004/12/22. doi: 10.1111/j.1600-0714.2004.00264.x
15. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L. Primary Sjogren syndrome in Spain: Clinical and immunologic expression in 1010 patients. Medicine. 2008 Jul;87(4):210-9. Epub 2008/07/16. doi: 10.1097/MD.0b013e318181e6af
16. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2006 Feb 21;103(8):2770-5. Epub 2006/02/16. doi: 10.1073/pnas.0510837103
17. Li H, Ice JA, Lessard CJ, Sivils KL. Interferons in Sjogren’s Syndrome: Genes, Mechanisms, and Effects. Frontiers in immunology. 2013;4:290. Epub 2013/09/26. doi: 10.3389/fimmu.2013.00290
18. Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, Casciola-Rosen L. Molecular subsetting of interferon pathways in Sjogren’s syndrome. Arthritis Rheumatol. 2015 May 18. doi: 10.1002/art.39204
19. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best practice & research Clinical rheumatology. 2008 Oct;22(5):883-96. Epub 2008/11/26. doi: 10.1016/j.berh.2008.09.007
20. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjogren’s syndrome. Arthritis and rheumatism. 2004 Sep;50(9):2897-902. Epub 2004/10/01. doi: 10.1002/art.20463
21. Gottenberg JE, Pallier C, Ittah M, Lavie F, Miceli-Richard C, Sellam J, Nordmann P, Cagnard N, Sibilia J, Mariette X. Failure to confirm coxsackievirus infection in primary Sjogren’s syndrome. Arthritis and rheumatism. 2006 Jun;54(6):2026-8. Epub 2006/05/30. doi: 10.1002/art.21906
22. Lee SJ, Lee JS, Shin MG, Tanaka Y, Park DJ, Kim TJ, Park YW, Lee SS. Detection of HTLV-1 in the labial salivary glands of patients with Sjogren’s syndrome: A distinct clinical subgroup? The Journal of rheumatology. 2012 Apr;39(4):809-15. Epub 2012/03/03. doi: 10.3899/jrheum.111075
23. Wang D, Coscoy L, Zylberberg M, Avila PC, Boushey HA, Ganem D, DeRisi JL. Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15687-92. Epub 2002/11/14. doi: 10.1073/pnas.242579699
24. Yin H, Cabrera-Perez J, Lai Z, Michael D, Weller M, Swaim WD, Liu X, Catalan MA, Rocha EM, Ismail N, Afione S, Rana NA, Di Pasquale G, Alevizos I, Ambudkar I, Illei GG, Chiorini JA. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjogren’s syndrome and in mice. Arthritis and rheumatism. 2013 Dec;65(12):3228-38. doi: 10.1002/art.38123
25. Smedile A, Niro MG, Rizzetto M. Detection of serum HDV RNA by RT-PCR. Methods in molecular medicine. 2004;95:85-93. Epub 2004/02/26. doi: 10.1385/1-59259-669-X:85
26. Biosystems A. April 2014. Available from: Http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_042380.pdf.
27. Chang J, Gudima SO, Tarn C, Nie X, Taylor JM. Development of a novel system to study hepatitis delta virus genome replication. Journal of virology. 2005 Jul;79(13):8182-8. Epub 2005/06/16. doi: 10.1128/JVI.79.13.8182-8188.2005
28. Bichko VV, Taylor JM. Redistribution of the delta antigens in cells replicating the genome of hepatitis delta virus. J Virol. 1996 Nov;70(11):8064-70. Epub 1996/11/01.
29. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS). J Vis Exp. 2009 (32). doi: 10.3791/1549
30. Burbelo PD, Ching KH, Mattson TL, Light JS, Bishop LR, Kovacs JA. Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems). Biochemical and biophysical research communications. 2007 Jan 26;352(4):889-95. doi: 10.1016/j.bbrc.2006.11.140
31. Zheng C, Voutetakis A, Goldstein B, Afione S, Rivera VM, Clackson T, Wenk ML, Boyle M, Nyska A, Chiorini JA, Vallant M, Irwin RD, Baum BJ. Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands. Toxicological sciences: An official journal of the Society of Toxicology. 2011 Sep;123(1):247-55. Epub 2011/06/01. doi: 10.1093/toxsci/kfr144
32. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nature medicine. 2010 Jun;16(6):662-4. Epub 2010/05/18. doi: 10.1038/nm.2145
33. Wong CW, Heng CL, Wan Yee L, Soh SW, Kartasasmita CB, Simoes EA, Hibberd ML, Sung WK, Miller LD. Optimization and clinical validation of a pathogen detection microarray. Genome biology. 2007;8(5):R93. Epub 2007/05/29. doi: 10.1186/gb-2007-8-5-r93
34. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nature reviews Gastroenterology & hepatology. 2010 Jan;7(1):31-40. Epub 2010/01/07. doi: 10.1038/nrgastro.2009.205
35. Netter HJ, Kajino K, Taylor JM. Experimental transmission of human hepatitis delta virus to the laboratory mouse. J Virol. 1993 Jun;67(6):3357-62. Epub 1993/06/01.
36. Ram M, Anaya JM, Barzilai O, Izhaky D, Porat Katz BS, Blank M, Shoenfeld Y. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmunity reviews. 2008 Sep;7(8):621-5. Epub 2008/07/08. doi: 10.1016/j.autrev.2008.06.008
37. Casey JL. Hepatitis delta virus. Berlin; New York: Springer; 2006. vii, 228 p.
38. Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lutgehetmann M. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. Journal of hepatology. 2014 Mar;60(3):538-44. doi: 10.1016/j.jhep.2013.11.010
39. Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. Viruses. 2010 Jan;2(1):189-212. Epub 2010/01/01. doi: 10.3390/v2010189
40. Mota S, Mendes M, Penque D, Coelho AV, Cunha C. Changes in the proteome of Huh7 cells induced by transient expression of hepatitis D virus RNA and antigens. J Proteomics. 2008 Apr 30;71(1):71-9. Epub 2008/06/11. doi: 10.1016/j.jprot.2007.12.002
41. Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lutgehetmann M. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. Journal of hepatology. 2015 Mar 17. doi: 10.1016/j.jhep.2015.03.011
42. Amengual MJ, Catalfamo M, Pujol A, Juarez C, Gelpi C, Rodriguez JL. Autoantibodies in chronic delta virus infection recognize a common protein of 46 kD in rat forestomach basal cell layer and stellate thymic epithelial cells. Clinical and experimental immunology. 1989 Oct;78(1):80-4. PubMed PMID: 2680184. Epub 1989/10/01.
43. Philipp T, Obermayer-Straub P, Manns MP. Autoantibodies in hepatitis delta. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1995;49(7-8):344-9. Epub 1995/01/01.
44. Zauli D, Crespi C, Bianchi FB, Craxi A, Pisi E. Autoimmunity in chronic liver disease caused by hepatitis delta virus. Journal of clinical pathology. 1986 Aug;39(8):897-9. Epub 1986/08/01.
45. Marcos M, Alvarez F, Brito-Zeron P, Bove A, Perez-De-Lis M, Diaz-Lagares C, Sanchez-Tapias JM, Ramos-Casals M. Chronic hepatitis B virus infection in Sjogren’s syndrome. Prevalence and clinical significance in 603 patients. Autoimmunity reviews. 2009 Jun;8(7):616-20. Epub 2009/04/28. doi: 10.1016/j.autrev.2009.02.007
46. Chen MH, Hsiao LT, Tsai CY, Huang YH, Chou CT. Clinical significance of chronic hepatitis B virus infection in patients with primary Sjogren’s syndrome. Clinical rheumatology. 2012 Feb;31(2):309-15. Epub 2011/08/03. doi: 10.1007/s10067-011-1814-2
47. El-Kamary SS, Hashem M, Saleh DA, Abdelwahab SF, Sobhy M, Shebl FM, Shardell MD, Strickland GT, Shata MT. Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus. J Pediatr. 2013 Jan;162(1):148-54. Epub 2012/08/14. doi: 10.1016/j.jpeds.2012.06.057
48. Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology. 1997 Mar;25(3):728-34. Epub 1997/03/01. doi: 10.1002/hep.510250339
49. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL. Geographic distribution and genetic variability of hepatitis delta virus genotype I. Virology. 1997 Jul 21;234(1):160-7. Epub 1997/07/21. doi: 10.1006/viro.1997.8644
50. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Jul 16. doi: 10.1016/S1473-3099(15)00074-2
51. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003 Aug;112(3):407-14. Epub 2003/08/05. doi: 10.1172/jci17704
52. Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, Medina F, Rosas J, Anaya JM, Font J, Group S-HS. Sjogren syndrome associated with hepatitis C virus: A multicenter analysis of 137 cases. Medicine. 2005 Mar;84(2):81-9.
53. Schiodt M, Greenspan D, Daniels TE, Nelson J, Leggott PJ, Wara DW, Greenspan JS. Parotid gland enlargement and xerostomia associated with labial sialadenitis in HIV-infected patients. J Autoimmun. 1989 Aug;2(4):415-25. Epub 1989/08/01.
54. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002 Dec;1(6):329-37. Epub 2003/07/10.
55. Koike K, Moriya K, Ishibashi K, Yotsuyanagi H, Shintani Y, Fujie H, Kurokawa K, Matsuura Y, Miyamura T. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):233-6. Epub 1997/01/07.
56. Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjogren’s syndrome in HTLV-1 tax transgenic mice. Nature. 1989 Sep 7;341(6237):72-4. Epub 1989/09/07. doi: 10.1038/341072a0
57. Pertovaara M, Korpela M, Uusitalo H, Pukander J, Miettinen A, Helin H, Pasternack A. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Annals of the rheumatic diseases. 1999 Jul;58(7):423-7.